Thus, H/K-HELP-DCVAC might be suitable for supplementing a weak antigen release by radiotherapy alone and suppressing Th1-dependent antitumor immunity in cooperation with ICIs treatment, which facilitates the generation of CTL specific to common cancer antigens (WT-1 and survivin) expressing on most cancers. This evidence concerns the gene BIRC5 and cancer.